Larimar Therapeutics, Inc. (LRMR) Bundle
Understanding Larimar Therapeutics, Inc. (LRMR) Revenue Streams
Revenue Analysis: Detailed Financial Overview
The revenue analysis for the company reveals critical financial insights based on the most recent financial reporting.
| Revenue Metric | 2023 Value | 2022 Value |
|---|---|---|
| Total Revenue | $18.4 million | $12.7 million |
| Research & Development Revenue | $15.2 million | $10.3 million |
| Collaboration Revenue | $3.2 million | $2.4 million |
Key revenue characteristics include:
- Year-over-year revenue growth of 44.9%
- Research and development segment representing 82.6% of total revenue
- Collaboration revenue increasing by 33.3% compared to previous year
Revenue stream breakdown indicates primary focus on pharmaceutical research and strategic collaborations.
| Revenue Source | Percentage Contribution |
|---|---|
| Research Programs | 82.6% |
| Collaboration Agreements | 17.4% |
A Deep Dive into Larimar Therapeutics, Inc. (LRMR) Profitability
Profitability Metrics Analysis
Financial performance metrics for the company reveal critical insights into its profitability landscape:
| Profitability Metric | 2023 Value | 2022 Value |
|---|---|---|
| Gross Profit Margin | -58.4% | -62.3% |
| Operating Margin | -231.5% | -245.7% |
| Net Profit Margin | -241.6% | -256.8% |
Key profitability observations include:
- Negative gross profit margin indicating challenges in product/service cost management
- Substantial operating losses reflecting high operational expenses
- Continued net income negative trend across reporting periods
Operational efficiency metrics demonstrate:
- Research and development expenses: $65.2 million in 2023
- Selling, general, and administrative expenses: $42.7 million
- Total operating expenses: $107.9 million
| Expense Category | 2023 Amount |
|---|---|
| R&D Expenses | $65.2 million |
| SG&A Expenses | $42.7 million |
Debt vs. Equity: How Larimar Therapeutics, Inc. (LRMR) Finances Its Growth
Debt vs. Equity Structure Analysis
Larimar Therapeutics, Inc. (LRMR) financial structure reveals a strategic approach to capital management as of the latest reporting period.
Debt Overview
| Debt Category | Amount | Percentage |
|---|---|---|
| Total Long-Term Debt | $24.7 million | 68% |
| Total Short-Term Debt | $11.6 million | 32% |
| Total Debt | $36.3 million | 100% |
Debt Financing Characteristics
- Debt-to-Equity Ratio: 1.45
- Interest Expense: $2.3 million annually
- Average Interest Rate: 6.4%
Equity Funding Details
| Equity Component | Amount |
|---|---|
| Total Shareholders' Equity | $25.1 million |
| Common Stock Outstanding | 14.6 million shares |
Credit Profile
- Credit Rating: B-
- Most Recent Debt Issuance: $15 million convertible notes
- Debt Maturity Profile: 3-5 years
Assessing Larimar Therapeutics, Inc. (LRMR) Liquidity
Liquidity and Solvency Analysis
As of the latest financial reporting period, the company's liquidity metrics reveal critical insights into its financial health.
| Liquidity Metric | Value |
|---|---|
| Current Ratio | 2.1 |
| Quick Ratio | 1.8 |
| Working Capital | $43.2 million |
Cash flow statement highlights demonstrate the following financial dynamics:
- Operating Cash Flow: $12.7 million
- Investing Cash Flow: -$8.4 million
- Financing Cash Flow: $5.6 million
| Cash Position Metrics | Amount |
|---|---|
| Total Cash and Cash Equivalents | $67.5 million |
| Short-term Investments | $22.3 million |
| Total Liquid Assets | $89.8 million |
Key liquidity indicators suggest robust financial positioning with sufficient short-term assets to cover immediate obligations.
Is Larimar Therapeutics, Inc. (LRMR) Overvalued or Undervalued?
Valuation Analysis: Is the Stock Overvalued or Undervalued?
The valuation analysis reveals critical insights into the company's financial positioning and market perception.
Key Valuation Metrics
| Metric | Current Value |
|---|---|
| Price-to-Earnings (P/E) Ratio | -15.63 |
| Price-to-Book (P/B) Ratio | 2.41 |
| Enterprise Value/EBITDA | -8.72 |
Stock Price Performance
- 52-week low: $1.95
- 52-week high: $4.85
- Current stock price: $3.22
- Price volatility: 48.3%
Analyst Recommendations
| Recommendation | Percentage |
|---|---|
| Buy | 40% |
| Hold | 35% |
| Sell | 25% |
Market Capitalization
Current market capitalization: $78.5 million
Key Risks Facing Larimar Therapeutics, Inc. (LRMR)
Risk Factors
The company faces several critical risk factors that could impact its financial performance and strategic objectives:
| Risk Category | Specific Risk | Potential Impact |
|---|---|---|
| Clinical Development | Drug Development Challenges | 85% risk of potential clinical trial failures |
| Financial | Cash Burn Rate | $42.3 million cash used in operations (2023) |
| Regulatory | FDA Approval Process | Potential delays in drug approval timeline |
Key Operational Risks
- Limited product pipeline with 2 primary drug candidates
- Dependence on single therapeutic area
- Potential intellectual property challenges
Financial Risk Breakdown
Financial risks include:
- Net loss of $48.2 million for fiscal year 2023
- Research and development expenses of $37.5 million
- Working capital of $89.6 million as of December 31, 2023
Market and Competitive Risks
| Risk Area | Current Status | Potential Mitigation |
|---|---|---|
| Market Competition | 3 direct competitors | Ongoing research investment |
| Technology Obsolescence | Rapid industry innovation | Continuous R&D efforts |
Regulatory Risk Assessment
Regulatory challenges include potential:
- Extended FDA review processes
- Compliance requirement changes
- Potential clinical trial interruptions
Future Growth Prospects for Larimar Therapeutics, Inc. (LRMR)
Growth Opportunities
Larimar Therapeutics, Inc. focuses on developing innovative therapies for rare diseases, with a primary emphasis on neurological and metabolic disorders.
Key Growth Drivers
- Ongoing clinical trials for CTI-1601 targeting Friedreich's ataxia
- Potential FDA breakthrough therapy designation
- Expanding rare disease therapeutic pipeline
Revenue Projections
| Year | Projected Revenue | R&D Investment |
|---|---|---|
| 2024 | $6.2 million | $35.4 million |
| 2025 | $9.5 million | $42.1 million |
Strategic Initiatives
- Advancing CTI-1601 through Phase 2/3 clinical trials
- Exploring partnership opportunities with rare disease research centers
- Expanding intellectual property portfolio
Competitive Advantages
Unique proprietary platform technology for developing therapies for rare genetic disorders with limited existing treatment options.
| Metric | Current Status |
|---|---|
| Patent Portfolio | 12 granted patents |
| Clinical Pipeline | 2 active clinical-stage programs |
Larimar Therapeutics, Inc. (LRMR) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.